These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9118164)

  • 41. Clinical pharmacokinetics of nisoldipine coat-core.
    Heinig R
    Clin Pharmacokinet; 1998 Sep; 35(3):191-208. PubMed ID: 9784933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X.
    Ozçelik F; Altun A; Ozbay G
    Clin Cardiol; 1999 May; 22(5):361-5. PubMed ID: 10326170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension.
    Hoglund C; Hutchinson HG
    Int J Clin Pract; 1998 Jun; 52(4):221-5. PubMed ID: 9744143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amlodipine and the total ischemic burden: circadian anti-ischemia program in Europe (CAPE) trial-methodology, safety and toleration. The Steering Committee members and all of the investigators.
    Detry JM
    Cardiology; 1994; 85 Suppl 2():24-30. PubMed ID: 7736484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma endothelin-1 concentrations in patients with coronary artery disease during stress test before and after nisoldipine administration.
    Letizia C; Barillà F; Cerci S; De Ciocchis A; Coassin S; Mastroianni MA; D'Ambrosio C; Campa PP; Scavo D
    Acta Cardiol; 1996; 51(2):165-72. PubMed ID: 8742913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. The DEFIANT-II Research Group.
    Eur Heart J; 1997 Jan; 18(1):31-40. PubMed ID: 9049513
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of nisoldipine on myocardial ischemia during exercise and during daily activity.
    Tzivoni D; Banai S; Botvin S; Zilberman A; Weiss TA; Gavish A; Medina A; Benhorin J; Rogel S; Caspi A
    Am J Cardiol; 1991 Mar; 67(7):559-64. PubMed ID: 2000786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained-release diltiazem reduces myocardial ischemic episodes in end-stage renal disease: a double-blind, randomized, crossover, placebo-controlled trial.
    Cice G; Di Benedetto A; D'Andrea A; D'Isa S; Ferrara L; Russo PE; Iacono A; Calabrò R
    J Am Soc Nephrol; 2003 Apr; 14(4):1006-11. PubMed ID: 12660335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nisoldipine improves ventricular function in rats with ischemic heart failure.
    Capasso JM
    J Mol Cell Cardiol; 1995 Sep; 27(9):1841-9. PubMed ID: 8523445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High blood pressure and calcium antagonism.
    Palma-Gámiz JL
    Cardiology; 1997; 88 Suppl 1():39-46. PubMed ID: 9118167
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nisoldipine in severe ischaemic left ventricular dysfunction.
    Pouleur H; Rousseau MF
    Eur Heart J; 1993 Jul; 14 Suppl A():45-7. PubMed ID: 8370362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of nisoldipine on the total ischaemic burden: the results of the ROCKET study.
    Fox K; Pool J; Vos J; Lubsen J
    Eur Heart J; 1991 Dec; 12(12):1283-7. PubMed ID: 1778193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical pharmacology of nisoldipine coat core.
    Zannad F
    Am J Cardiol; 1995 Apr; 75(13):41E-45E. PubMed ID: 7726124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement of silent myocardial ischaemia and reduction of plasma fibrinogen during nisoldipine therapy in occult coronary arterial disease.
    Salmasi AM; Salmasi S; MacDonald G; Nicolaides AN
    Int J Cardiol; 1991 Apr; 31(1):71-80. PubMed ID: 2071252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment effects on the total ischaemic burden and prognostic implications.
    Deanfield J
    Eur Heart J; 1996 Dec; 17 Suppl G():64-8. PubMed ID: 8960459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New aspects of the treatment of ischemic heath disease with calcium antagonists. Proceedings of the International Nisoldipine Symposium. Düsseldorf, Germany, March 27-29, 1992.
    J Cardiovasc Pharmacol; 1992; 20 Suppl 5():S1-81. PubMed ID: 1282607
    [No Abstract]   [Full Text] [Related]  

  • 57. Why is nisoldipine a specific agent in ischemic left ventricular dysfunction?
    Knorr AM
    Am J Cardiol; 1995 Apr; 75(13):36E-40E. PubMed ID: 7726122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of angina pectoris with calcium antagonists: long-term follow-up.
    Behar S
    Cardiovasc Drugs Ther; 1998 Apr; 12 Suppl 1():119-24. PubMed ID: 9642485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DEFIANT-II: a study of nisoldipine CC after myocardial infarction. Doppler flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy investigators.
    Hall R
    Cardiovasc Drugs Ther; 1997 Jan; 10 Suppl 3():881. PubMed ID: 9126677
    [No Abstract]   [Full Text] [Related]  

  • 60. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence.
    Mason RP
    Atherosclerosis; 2002 Dec; 165(2):191-9. PubMed ID: 12417269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.